🇺🇸 FDA
Pipeline program

Allogeneic MSC (AlloMSC)

NSFC30772014

Phase 2 mab active

Quick answer

Allogeneic MSC (AlloMSC) for Refractory Systemic Lupus Erythematosus is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Refractory Systemic Lupus Erythematosus
Phase
Phase 2
Modality
mab
Status
active

Clinical trials